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Autoimmune diseases (AIDs) as a whole represent a major health concern and remain 
a medical and scientific challenge. Some of them, such as multiple sclerosis or type 1 
diabetes, have been actively investigated for many decades. Autoimmune myopathies 
(AIMs), also referred to as idiopathic inflammatory myopathies or myositis, represent a 
group of very severe AID for which we have a more limited pathophysiological knowl-
edge. AIM encompass a group of, individually rare but collectively not so uncommon, 
diseases characterized by symmetrical proximal muscle weakness, increased serum 
muscle enzymes such as creatine kinase, myopathic changes on electromyography, 
and several typical histological patterns on muscle biopsy, including the presence of 
inflammatory cell infiltrates in muscle tissue. Importantly, some AIMs are strongly related 
to cancer. Here, we review the current knowledge on the most prevalent forms of AIM 
and, notably, the diagnostic contribution of autoantibodies.
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Bohan and Peter originally classified myositis into two major groups based on clinical, electro-
myographical, and immunohistological features: polymyositis (PM) and dermatomyositis (DM), 
the latter associating skin manifestations to muscle weakness (1). Indeed, the presence of a muscle 
inflammatory infiltrate is a hallmark in autoimmune myopathies (AIM), but it is not discriminat-
ing enough since it cannot per se identify each AIM subtype and maybe present in some types of 
muscular dystrophies. Sporadic inclusion-body myositis (sIBM), resistant to steroids and associating 
both autoimmune and degenerative components, was individualized more recently (2, 3). When 
defined according to the Bohan and Peter classification, PM was initially considered as the archetype 
of AIM, although it seems to be an uncommon pathological entity, some experts even arguing that 
it barely exists (4, 5). Indeed, according to newer, more stringent criteria, most AIM initially diag-
nosed as PM were reclassified as overlap myositis (OM), a condition with not only musculoskeletal 
but also extramuscular involvement and/or association to autoantibodies (aAbs) (6). Anti-tRNA 
synthetase syndrome (ARS syndrome) is the archetype of OM combining myositis to interstitial 
lung disease, arthritis, Raynaud phenomenon, and mechanic’s hands. Hence, ARS syndrome has 
been considered by some authors as an atypical clinical form of DM (7). OM and DM are the more 
frequent AIM (67 and 18%, respectively, according to Troyanov et al.) (6). Around 60% of patients 
with AIM have myositis-specific aAbs (8), and it is presumable that this frequency will reach higher 
levels when appropriate diagnostic immunoassays are more widely used and new specificities are 
discovered (Figure 1). The more recently identified entity is represented by necrotizing autoimmune 
myopathies (NAM), also sometimes referred to as immune-mediated necrotizing myopathies. This 
group of severe AIM is characterized by minimal inflammatory infiltrate but predominant necrotic 
FiGURe 1 | Schematic view of pathological pattern of inflammatory myopathies and proven degree of pathogenicity of specific autoantibodies 
relative to each iM subtypes. Bold: high risk of neoplasia, Italics: amyopathic DM. NAM, necrotizing autoimmune myopathy; DM, dermatomyositis; ARS, 
anti-t-rna synthetase syndrome; sIBM, sporadic inclusion-body myositis.
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fibers on muscle biopsy (9). The discovery of aAbs directed to 
components of the signal recognition particle (SRP) (10) or to 
3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) 
(11, 12) has been instrumental in identifying this entity.
DeRMATOMYOSiTiS AnD OveRLAP 
MYOSiTiS
Dermatomyositis affects both children and adults, most fre-
quently women, and is associated with cancer in adults and 
calcinosis in children. The clinical presentation of DM includes 
skin manifestations that usually precede muscle weakness (13). 
Skin features are varied and some are very specific such as a 
violaceous eruption (Gottron’s rash) on the knuckles which may 
evolve into a scaling discoloration (Gottron’s papule), purple 
periorbital heliotrope rash with edema notably on upper eyelids, 
while others are less specific as erythematous rash on the face, 
knees, elbows, malleoli, neck, anterior chest (in a V-sign), back 
and shoulders (in a shawl sign), or periungeal erythema, painful 
to pressure (manicure sign) (14). Muscle weakness constantly 
involves limb girdle muscles and less frequently respiratory and 
pharyngeal muscles (15).
As a consequence of myofiber injury, creatine kinase is 
released and found elevated in the serum. Electromyography and 
MRI may also be useful to evaluate disease topography and guide 
muscle biopsy. In the presence of typical skin manifestations, 
muscle biopsy is not always performed. When it is the case, histo-
logical analysis establishes the diagnosis by showing features that, 
in addition to inflammation and myofiber necrosis plus regen-
eration, distinguish DM from other myositis pattern: endomysial 
microangiopathy with membrane attack complex (C5b–9) 
capillaries staining and ischemic fiber lesions. Also, in DM, 
mononuclear cells composed of macrophages, B lymphocytes, 
and plasmacytoid dendritic cells (pDC) predominantly infiltrate 
perivascular and perimysial areas (Figure 2A), whereas normal 
muscle fibers do not express detectable levels of HLA class I 
molecules (16, 17), sarcolemmal re-expression of HLA class I is a 
hallmark of most types of myositis, with a perifascicular enhance-
ment, in the case of DM (15). Recently, a lymphoid follicle variant 
of juvenile DM has been described and is associated with a severe 
prognosis (18).
Several aAbs are associated with different clinical forms of 
DM and have an impact on the prognosis (19). Anti-Mi2 aAbs 
are positive in 10–20% of DM and associated with a low risk of 
associated cancer and a better prognosis (20). Anti-Mi2 aAbs are 
directed against the nucleosome remodeling histone-deacetylase 
(NURD) nuclear protein complex, implicated in DNA transcrip-
tion. In contrast, anti-TIF1γ aAbs are positive in more than 
10% of DM and the presence of this aAb is highly associated 
with cancer (21). As in other DM, transcription intermediary 
factor 1 (TIF1) family proteins, a nuclear transcription factor 
(22), is implicated in the TGFβ pathway (23). Anti-melanoma 
differentiation-associated gene 5 (anti-MDA-5) aAbs recognize 
an innate immune protein implicated in antiviral response and 
is positive in about 10–20% of DM (24). They are more frequent 
in amyopathic forms of DM, with severe interstitial lung disease 
and ulceral lesions (25). Anti-NXP-2 aAbs are more frequent in 
juvenile DM and are associated with calcinosis. Others, such as 
anti-small ubiquitin-like modifier activating enzyme (anti-SAE) 
(26, 27) or anti-cortactin (28), are currently found more rarely 
and also less routinely sought for.
FiGURe 2 | Pathological features of inflammatory myopathies. 
Pathological features of DM. (A) Perimysial and perivascular inflammatory cell 
infiltrate. Perifascicular myofiber atrophy (arrow heads). Pathological features 
of anti-HMGCR NAM. (B) Necrotic (asterisk) and regenerative (arrows) 
myofibers, sparsely infiltrate pathological features of sIBM. (C) Invaded fibers 
by inflammatory cells. (D) Rimmed vacuoles. (e) Ragged-red fiber. (F) P62 
aggregates. (G) Immunohistochemichal evidence of MHC-I myofibers 
expression. (H) C5b–9 membrane attack complex in capillaries. Composition 
of the endomysial inflammatory infiltrate (i) CD4+ cells, (J) CD8+ cells, (K) 
CD68+ cells, and (L) rare CD20+ cells. All features provided by Dr. Jean-
Philippe Simon.
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The physiopathology of DM is not well understood (13, 29). 
Muscle biopsy shows not only immune cells infiltrates but also 
C5b–9 deposits. Since DM is strongly associated with the pres-
ence of aAbs, it is presumable, yet not clearly demonstrated, that 
these aAbs may activate complement triggering the release of 
pro-inflammatory cytokines, upregulation of adhesion molecules 
on endothelial cells, and migration of B and CD4+ T lymphocytes 
and pDC (30–32). Type 1 interferons produced by pDC, in turn, 
stimulate the production of pro-inflammatory cytokines and 
enhance the expression or HLA class I and class II molecules (33).
Dermatomyositis associated with anti-TIF1γ aAbs is strongly 
related to cancer (21). One (non-demonstrated) hypothesis is 
that somatic mutations in cancer cells may have occurred in the 
TIF1γ gene, yielding to the production of an immunogenic non-
self neoantigen, which could lead to autoimmunity after epitope 
spreading of the B cell response, following the example of POLR3 
mutations in systemic sclerosis (34). This hypothesis would imply 
that anti-TIF1γ aAbs and/or T cells are directly pathogenic, which 
remains to be demonstrated.
High-dose oral corticosteroids (1  mg/kg) represent the 
first-line treatment in DM (13, 35). Methylprednisolone bolus 
(500  mg/day–1  g/day during 3  days) can be considered when 
severe motor deficit or life-threatening extramuscular manifes-
tations are present. Immunosuppressive treatments are used as 
second-line treatment (methotrexate, azathioprine) if corticos-
teroid treatment is ineffective or if the patient has developed 
serious corticosteroid-related side effects. Others treatment can 
be considered as third-line therapy (36): intravenous immuno-
globulins, ciclosporin, cyclophosphamide, or rituximab.
Anti-tRNA synthetase syndromes are defined by aAbs 
positivity directed against one aminoacyl-tRNA synthetase 
enzyme. ARS syndrome has been initially described as a spe-
cific clinical presentation regrouping myositis, lung interstitial 
disease, arthritis, mechanic’s hands, and Raynaud phenomenon. 
There is some clinical variation depending on the aAb. Patients 
may initially present with an isolated lung involvement. This 
syndrome is associated with specific aAb directed against one 
of the aminoacyl-tRNA-synthetase enzymes that enable tRNA 
to bind to specific amino acids. Each enzyme is specific for an 
amino acid/tRNA pair (37). The most common aAbs, by far, 
recognize histidyl-tRNA-synthetase (anti-JO-1), others less 
frequently alanyl-tRNA-synthetase (anti-PL-12) or threonyl-
tRNA-synthetase (anti-PL-7). The pathological pattern is close 
to that of DM (38). Recent pathological studies argue for some 
specific features, such as a HLA-DR expression, with a specific 
perifascicular pattern (39), as the topography of necrotic myofib-
ers (40), ARS syndrome usually respond to corticosteroids and 
immunosuppressive drugs. Rituximab can be considered in case 
of severe muscular weakness or intestitial lung disease (41, 42).
neCROTiZinG AUTOiMMUne 
MYOPATHieS
Although their frequency is difficult to determine precisely at 
this stage, NAM probably account for 20% of AIM. They mainly 
affect adults, most frequently women. NAM clinical presentation 
is characterized by symmetrical and proximal muscle weakness 
leading to muscle atrophy, which can be associated with intersti-
tial lung disease, dysphagia, or dyspnea (43, 44). Some patients 
present with progressive, corticosteroid resistant myositis, while 
other forms may masquerade as a muscular dystrophy, yielding 
to a delay in diagnosis.
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Creatine kinase is generally highly elevated (>4,000  U/L) 
and correlated with disease severity during follow-up (10, 45, 
46). Electrocardiogram may be abnormal (13, 47). Muscle MRI 
can be useful to confirm muscle involvement, evaluate disease 
topography, and guide the biopsy.
The prominent histological finding in NAM is the presence 
of necrotic and regenerative myofibers. Atrophic and irregularly 
shaped myofibers are also present (Figure  2B). When present, 
inflammatory infiltrates are mostly composed of macrophages 
(48, 49). Yet, a mild lymphocytic infiltrate can be found in some 
patients with presence of CD4+ and CD8+ T cells, B cells, and 
dendritic cells restricted to the perivascular and endomysial 
regions. C5b–9 deposits can be found on necrotic myofibers, 
sarcoplasm of myofibers, and in some capillaries (50). As opposed 
to other AIM, HLA class I re-expression is mild and scattered, if 
present (43).
Necrotizing autoimmune myopathies are strongly associated 
with specific aAbs in two-third of cases: anti-SRP or anti-HMGCR 
aAbs. Anti-SRP aAbs mainly, but not exclusively, target the 54 kDa 
subunit of the SRP complex localized in the cytoplasm or at the 
surface of the endoplasmic reticulum, when bound to the SRP 
receptor. SRP allows the transfer of nascent proteins to the endo-
plasmic reticulum during protein synthesis. Anti-SRP aAbs from 
patients are able to block this mechanism (51, 52). Younger patients 
with anti-SRP aAbs may develop a form mimicking a muscular 
dystrophy (53). Anti-HMGCR aAbs target the catalytic domain of 
hydroxyl-methylglutaryl-coenzyme A reductase. This endoplas-
mic reticulum membrane enzyme is involved in the biosynthesis 
of cholesterol and is the pharmacological target of the hypocho-
lesterolemic drugs, statins (11, 54). We developed quantitative 
immune-assays based on the ALBIA/Luminex technology, which 
showed that anti-SRP and anti-HMGCR aAbs levels correlate with 
disease activity, as evaluated by CK levels and muscle strength (10, 
45). One-third of NAM patients still do not exhibit known aAbs, 
but it is anticipated that new specificities will be discovered.
Necrotizing autoimmune myopathies pathophysiology is still 
poorly understood, notably because of a lack of animal models. An 
autoimmune mechanism has been early suggested by the associa-
tion between NAM and the above-mentioned anti-SRP aAbs (50, 
55). It should be reminded that both anti-SRP and anti-HMGCR 
aAbs target intracellular proteins and the question of how they 
may reach their cognate antigen remains a mystery. However, the 
paucity of inflammatory infiltrate, the mild re-expression of HLA 
class I by non-necrotic and non-regenerative myofibers, and the 
pathogenic implication of antibodies suggested by the correla-
tion between level of aAbs and disease activity strongly argues 
for a humoral-related disease with aAb-dependent complement-
mediated myofiber attack, eventually leading to myofiber 
necrosis and regeneration from satellite cells (11, 45, 54, 56). The 
presence of C5b–9 deposits on muscle cells further supports the 
hypothesis of a direct role of anti-SRP and anti-HMGCR aAbs. 
Approximately half of anti-HMGCR positive NAM patients have 
been exposed to statins, molecule that inhibit activity and pro-
voke overexpression of HMGCR (11, 54). It cannot be excluded 
that the binding of a statin to HMGCR might also change the 
conformation of the protein, leading to the generation of new 
epitopes to which the immune system would not be tolerant (44). 
We have some experimental evidence suggesting that anti-SRP 
and anti-HMGCR aAbs are directly pathogenic in vitro on muscle 
cells and in vivo in mice.
Currently, there is no validated therapeutic strategy for NAM. 
High-dose oral corticosteroids (1  mg/kg) are the first line of 
treatment (47). However, they are not sufficient to control dis-
ease and need to be combined with immunosuppressive therapy 
(methotrexate, azathioprine, and cyclosporine) and intravenous 
immunoglobulins (44, 57, 58). In resistant patients, due to the 
presumable pathogenic role of aAbs, plasmapheresis can be help-
ful and lead to clinical improvement. Also, some studies have 
shown the interest to treat patients with rituximab (50, 59) or 
cyclophosphamide (60). A recent study has evidenced an associa-
tion between anti-HMGCR positive and seronegative NAM to 
neoplasia, whereas anti-SRP positive NAM was not related to 
cancer (61). This study also showed that the presence of cancer is 
a main determinant of outcome. In case of exposure, statin treat-
ment must be immediately discontinued. Statin exposed patients 
seem to have a better response to treatment (45, 62). Finally, it 
should be stated that statins may be present in the food (some 
mushrooms or yeast for instance) and patients could have been 
exposed without being aware of it. Therefore, absence of statin 
exposure should not discard this diagnosis.
SPORADiC inCLUSiOn-BODY MYOSiTiS
Sporadic inclusion-body myositis is the most frequently acquired 
myopathy in patients over 50 years (63). Its natural course is quite 
slow with a progressive muscular weakness worsening year after 
year often leading to a loss of ambulation, respiratory muscle 
weakness, and dysphagia (3). sIBM affect striated muscle with a 
characteristic pattern affecting quadriceps, fingers deep flexors, 
and possibly pharyngeal muscles.
Pathological criteria have been of major importance to retain 
the diagnosis of sIBM (2). The new criteria no longer require 
bringing together all the pathological hallmarks (64): they include 
presence of inflammatory infiltrates (Figure  2C) with mononu-
clear cell invasion of non-necrotic muscle fibers (partial invasion), 
vacuolated muscle fibers (Figure  2D), and intracellular amyloid 
protein deposits or 15–18 nm tubulofilaments in the cytoplasm or 
the nucleus by electron microscopy. Pathological marks have been 
historically divided between inflammatory and degenerative signs. 
Degenerative signs are based on the presence of abnormal accu-
mulation of β-amyloïdogenic deposits (65–67). These deposits are 
located in the muscle fibers of sIBM patients, whereas they used to 
be observed extracellularly in Alzheimer’s diseases. Others proteins 
known to be implicated in degenerative processes have been found, 
such as ubiquitin (68). The two main pathways of protein degra-
dation, 26S-proteasome (69) and autophagy (70), are impaired, 
the latter generating rimmed vacuoles. Proteins linked to these 
pathways are accumulated, as demonstrated by immunostaining, 
such as p62 or TDP43 (Figure 2F); they represent sensitive patho-
logical markers of sIBM (71, 72). On the other hand, inflamma-
tory infiltrates also accompany these degenerative signs. They are 
predominantly composed of CD8+ T cells and macrophages and a 
minority of CD4+ T cells and CD20+ B cells (Figures 2I–L). CD8+ T 
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cells and macrophages can invade non-necrotic muscle fibers (73). 
HLA class I molecules have a diffuse and high overexpression at 
the sarcolemma (16, 74), typically more intense than in other AIMs 
(Figure 2G). It is presumable that these HLA molecules can present 
yet unknown muscle auto-antigens to CD8+ T cells. Complement 
C5b9 membrane attack complex is usually pathologically expressed 
by capillaries (Figure 2H). Moreover, Pestronk recently identified 
mitochondrial abnormalities (COX negative and/or ragged-red 
fibers; Figure 2E) as hallmarks of sIBM pathological pattern (38). 
Yet, despite these signs of probable autoimmunity, sIBM patients 
respond poorly to immune treatments (3).
The fundamental question remains as to whether sIBM is pri-
marily an inflammatory or degenerative myopathy. We and others 
have defended elsewhere the view that the starter of sIBM is more 
likely to be inflammation within muscle (75). Indeed, there are 
few arguments to consider that degeneration could be the initial 
event. The strongest would be the lack of efficiency of immuno-
suppressive drugs (76–79), although two trials assessing massive 
immunosuppression have reported a strength stabilization (80, 
81). Also, the initially selective muscular pattern (quadriceps and 
fingers deep flexors) is rather a genetic myopathy trait. It should 
be mentioned here that hereditary IBM (hIBM) may be secondary 
to mutation in the valosin-containing protein (VCP) (82, 83) or 
UDP-N-acetylglucosamine-2-epimerase/N-acetylmannosamine 
kinase (GNE) (84) gene. Yet, hIBM pathological patterns only 
contain degenerative elements and no immune infiltrates, indi-
cating that muscle degeneration per se is probably not sufficient 
to elicit a myositis process. Alternatively, more arguments can be 
found to support inflammation as an initial trigger. They include 
association of sIBM to other autoimmune diseases (AIDs) (85), 
to aAbs directed against cytosolic 5′-nucleotidase1A (86, 87), or 
to some HLA alleles (88). Also, exposure of human myotubes to 
IL-1β causes intracellular aggregation of β-amyloid (89).
SUMMARY
Autoimmune myopathy represents a group of severe inflamma-
tory diseases. The search for aAbs has substantially improved 
their diagnosis and may also inform on their prognosis, notably 
when there is an associated risk of cancer. Studying myositis 
offers exciting pathophysiological and clinical research perspec-
tives in immunology. Important issues relate to the nature of the 
association between cancer and adult DM, the pathogenicity of 
aAbs in NAM, the elucidation of the primum movens of sIBM, 
the identification of new aAbs and therapeutic targets, and the 
validation of therapeutic protocols using immunosuppressants or 
biodrugs. Clearly, the development of appropriate animal models 
will be instrumental in this perspective.
AUTHOR COnTRiBUTiOnS
OB gave an oral communication on this topic at Immunocolombia 
2015 and coordinated the redaction of this mini review. JM and 
JPS wrote the first draft of this article. JPS designed figures. IM 
and FJ critically reviewed the manuscript for important intel-
lectual content. All authors approved the final version.
FUnDinG
This work was funded in part by the Association Française contre 
les Myopathies.
ReFeRenCeS
1. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). 
N Engl J Med (1975) 292:344–7. doi:10.1056/NEJM197502132920706 
2. Griggs RC, Askanas V, DiMauro S, Engel A, Karpati G, Mendell JR, et  al. 
Inclusion body myositis and myopathies. Ann Neurol (1995) 38:705–13. 
doi:10.1002/ana.410380504 
3. Benveniste O, Guiguet M, Freebody J, Dubourg O, Squier W, Maisonobe T, 
et  al. Long-term observational study of sporadic inclusion body myositis. 
Brain (2011) 134:3176–84. doi:10.1093/brain/awr213 
4. Amato AA, Griggs RC. Unicorns, dragons, polymyositis, and other mytholog-
ical beasts. Neurology (2003) 61:288–9. doi:10.1212/WNL.61.3.288 
5. van der Meulen MF, Bronner IM, Hoogendijk JE, Burger H, van Venrooij WJ, 
Voskuyl AE, et  al. Polymyositis: an overdiagnosed entity. Neurology (2003) 
61:316–21. doi:10.1212/WNL.61.3.316 
6. Troyanov Y, Targoff IN, Tremblay JL, Goulet JR, Raymond Y, Senecal 
JL. Novel classification of idiopathic inflammatory myopathies based on 
overlap syndrome features and autoantibodies: analysis of 100 French 
Canadian patients. Medicine (Baltimore) (2005) 84:231–49. doi:10.1097/01.
md.0000173991.74008.b0 
7. Troyanov Y, Targoff IN, Payette MP, Raynauld JP, Chartier S, Goulet JR, 
et  al. Redefining dermatomyositis: a description of new diagnostic criteria 
that differentiate pure dermatomyositis from overlap myositis with derma-
tomyositis features. Medicine (Baltimore) (2014) 93:318–32. doi:10.1097/
MD.0000000000000222 
8. Mammen AL. Autoimmune myopathies: autoantibodies, phenotypes and 
pathogenesis. Nat Rev Neurol (2011) 7:343–54. doi:10.1038/nrneurol. 
2011.63 
9. Hoogendijk JE, Amato AA, Lecky BR, Choy EH, Lundberg IE, Rose MR, 
et al. 119th ENMC international workshop: trial design in adult idiopathic 
inflammatory myopathies, with the exception of inclusion body myositis, 
10-12 October 2003, Naarden, The Netherlands. Neuromuscul Disord (2004) 
14:337–45. doi:10.1016/j.nmd.2004.02.006 
10. Benveniste O, Drouot L, Jouen F, Charuel JL, Bloch-Queyrat C, Behin A, et al. 
Correlation of anti-signal recognition particle autoantibody levels with cre-
atine kinase activity in patients with necrotizing myopathy. Arthritis Rheum 
(2011) 63:1961–71. doi:10.1002/art.30344 
11. Mammen AL, Chung T, Christopher-Stine L, Rosen P, Rosen A, Doering KR, 
et al. Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reduc-
tase in patients with statin-associated autoimmune myopathy. Arthritis Rheum 
(2011) 63:713–21. doi:10.1002/art.30156 
12. Drouot L, Allenbach Y, Jouen F, Charuel JL, Martinet J, Meyer A, et  al. 
Exploring necrotizing autoimmune myopathies with a novel immunoassay for 
anti-3-hydroxy-3-methyl-glutaryl-CoA reductase autoantibodies. Arthritis 
Res Ther (2014) 16:R39. doi:10.1186/ar4468 
13. Dalakas MC. Inflammatory muscle diseases. N Engl J Med (2015) 373:393–4. 
doi:10.1056/NEJMc1506827 
14. Iaccarino L, Ghirardello A, Bettio S, Zen M, Gatto M, Punzi L, et al. The clin-
ical features, diagnosis and classification of dermatomyositis. J Autoimmun 
(2014) 4(8–49):122–7. doi:10.1016/j.jaut.2013.11.005 
15. Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet (2003) 
362:971–82. doi:10.1016/S0140-6736(03)14368-1 
16. Emslie-Smith AM, Arahata K, Engel AG. Major histocompatibility complex 
class I antigen expression, immunolocalization of interferon subtypes, and 
T cell-mediated cytotoxicity in myopathies. Hum Pathol (1989) 20:224–31. 
doi:10.1016/0046-8177(89)90128-7 
6Simon et al. Myositis in 2015
Frontiers in Immunology | www.frontiersin.org June 2016 | Volume 7 | Article 234
17. McDouall RM, Dunn MJ, Dubowitz V. Expression of class I and class II 
MHC antigens in neuromuscular diseases. J Neurol Sci (1989) 89:213–26. 
doi:10.1016/0022-510X(89)90023-3 
18. Radke J, Pehl D, Aronica E, Schonenberg-Meinema D, Schneider U, 
Heppner FL, et al. The lymphoid follicle variant of dermatomyositis. Neurol 
Neuroimmunol Neuroinflamm (2014) 1:e19. doi:10.1212/NXI.0000000000 
000019 
19. Ghirardello A, Bassi N, Palma L, Borella E, Domeneghetti M, Punzi L, et al. 
Autoantibodies in polymyositis and dermatomyositis. Curr Rheumatol Rep 
(2013) 15:335. doi:10.1007/s11926-013-0335-1 
20. Selva-O’Callaghan A, Labrador-Horrillo M, Solans-Laque R, Simeon-Aznar 
CP, Martinez-Gomez X, Vilardell-Tarres M. Myositis-specific and myosi-
tis-associated antibodies in a series of eighty-eight Mediterranean patients 
with idiopathic inflammatory myopathy. Arthritis Rheum (2006) 55:791–8. 
doi:10.1002/art.22237 
21. Trallero-Araguas E, Rodrigo-Pendas JA, Selva-O’Callaghan A, Martinez-
Gomez X, Bosch X, Labrador-Horrillo M, et  al. Usefulness of anti-p155 
autoantibody for diagnosing cancer-associated dermatomyositis: a systematic 
review and meta-analysis. Arthritis Rheum (2012) 64:523–32. doi:10.1002/
art.33379 
22. Fujimoto M, Hamaguchi Y, Kaji K, Matsushita T, Ichimura Y, Kodera M, et al. 
Myositis-specific anti-155/140 autoantibodies target transcription intermedi-
ary factor 1 family proteins. Arthritis Rheum (2012) 64:513–22. doi:10.1002/
art.33403 
23. Amemiya K, Semino-Mora C, Granger RP, Dalakas MC. Downregulation of 
TGF-beta1 mRNA and protein in the muscles of patients with inflammatory 
myopathies after treatment with high-dose intravenous immunoglobulin. Clin 
Immunol (2000) 94:99–104. doi:10.1006/clim.1999.4823 
24. Allenbach Y, Leroux G, Suarez-Calvet X, Preusse C, Gallardo E, Hervier B, et al. 
Dermatomyositis with or without anti-melanoma  differentiation-associated 
gene 5 antibodies: common interferon signature but distinct NOS2 
expression. Am J Pathol (2016) 186:691–700. doi:10.1016/j.ajpath.2015. 
11.010 
25. Hamaguchi Y, Kuwana M, Hoshino K, Hasegawa M, Kaji K, Matsushita T, 
et  al. Clinical correlations with dermatomyositis-specific autoantibodies in 
adult Japanese patients with dermatomyositis: a multicenter  cross-sectional 
study. Arch Dermatol (2011) 147:391–8. doi:10.1001/archdermatol.2011.52 
26. Betteridge ZE, Gunawardena H, Chinoy H, North J, Ollier WE, Cooper RG, 
et  al. Clinical and human leucocyte antigen class II haplotype associations 
of autoantibodies to small ubiquitin-like modifier enzyme, a dermatomyo-
sitis-specific autoantigen target, in UK Caucasian adult-onset myositis. Ann 
Rheum Dis (2009) 68:1621–5. doi:10.1136/ard.2008.097162 
27. Muro Y, Sugiura K, Akiyama M. Low prevalence of anti-small ubiquitin-like 
modifier activating enzyme antibodies in dermatomyositis patients. 
Autoimmunity (2013) 46:279–84. doi:10.3109/08916934.2012.755958 
28. Labrador-Horrillo M, Martinez MA, Selva-O’Callaghan A, Trallero-Araguas 
E, Grau-Junyent JM, Vilardell-Tarres M, et al. Identification of a novel myo-
sitis-associated antibody directed against cortactin. Autoimmun Rev (2014) 
13:1008–12. doi:10.1016/j.autrev.2014.08.038 
29. Haq SA, Tournadre A. Idiopathic inflammatory myopathies: from immuno-
pathogenesis to new therapeutic targets. Int J Rheum Dis (2015) 18:818–25. 
doi:10.1111/1756-185X.12736 
30. Page G, Chevrel G, Miossec P. Anatomic localization of immature and mature 
dendritic cell subsets in dermatomyositis and polymyositis: interaction with 
chemokines and Th1 cytokine-producing cells. Arthritis Rheum (2004) 
50:199–208. doi:10.1002/art.11428 
31. Greenberg SA, Pinkus JL, Pinkus GS, Burleson T, Sanoudou D, Tawil R, et al. 
Interferon-alpha/beta-mediated innate immune mechanisms in dermatomy-
ositis. Ann Neurol (2005) 57:664–78. doi:10.1002/ana.20464 
32. Suarez-Calvet X, Gallardo E, Nogales-Gadea G, Querol L, Navas M, Diaz-
Manera J, et al. Altered RIG-I/DDX58-mediated innate immunity in derma-
tomyositis. J Pathol (2014) 233:258–68. doi:10.1002/path.4346 
33. Eloranta ML, Barbasso Helmers S, Ulfgren AK, Ronnblom L, Alm GV, 
Lundberg IE. A possible mechanism for endogenous activation of the 
type I interferon system in myositis patients with anti-Jo-1 or anti-Ro 52/
anti-Ro 60 autoantibodies. Arthritis Rheum (2007) 56:3112–24. doi:10.1002/ 
art.22860 
34. Joseph CG, Darrah E, Shah AA, Skora AD, Casciola-Rosen LA, Wigley 
FM, et  al. Association of the autoimmune disease scleroderma with an 
immunologic response to cancer. Science (2014) 343:152–7. doi:10.1126/science. 
1246886 
35. Choy EH, Hoogendijk JE, Lecky B, Winer JB. Immunosuppressant and immu-
nomodulatory treatment for dermatomyositis and polymyositis. Cochrane 
Database Syst Rev (2005) 4:CD003643. doi:10.1002/14651858.CD003643.
pub2 
36. Marie I, Mouthon L. Therapy of polymyositis and dermatomyositis. 
Autoimmun Rev (2011) 11:6–13. doi:10.1016/j.autrev.2011.06.007 
37. Cavarelli J, Moras D. Recognition of tRNAs by aminoacyl-tRNA synthetases. 
FASEB J (1993) 7:79–86. 
38. Pestronk A. Acquired immune and inflammatory myopathies: pathologic 
classification. Curr Opin Rheumatol (2011) 23:595–604. doi:10.1097/
BOR.0b013e32834bab42 
39. Aouizerate J, De Antonio M, Bassez G, Gherardi RK, Berenbaum F, Guillevin 
L, et  al. Myofiber HLA-DR expression is a distinctive biomarker for anti-
synthetase-associated myopathy. Acta Neuropathol Commun (2014) 2:154. 
doi:10.1186/s40478-014-0154-2 
40. Mescam-Mancini L, Allenbach Y, Hervier B, Devilliers H, Mariampillay K, 
Dubourg O, et al. Anti-Jo-1 antibody-positive patients show a characteristic 
necrotizing perifascicular myositis. Brain (2015) 138:2485–92. doi:10.1093/
brain/awv192 
41. Allenbach Y, Guiguet M, Rigolet A, Marie I, Hachulla E, Drouot L, et  al. 
Efficacy of rituximab in refractory inflammatory myopathies associated with 
anti-synthetase auto-antibodies: an open-label, phase II trial. PLoS One (2015) 
10:e0133702. doi:10.1371/journal.pone.0133702 
42. Andersson H, Sem M, Lund MB, Aalokken TM, Gunther A, Walle-
Hansen R, et  al. Long-term experience with rituximab in anti-synthetase 
 syndrome-related interstitial lung disease. Rheumatology (Oxford) (2015) 
54:1420–8. doi:10.1093/rheumatology/kev004 
43. Bergua C, Chiavelli H, Simon JP, Boyer O, Jouen F, Stenzel W, et al. Immune-
mediated necrotizing myopathy. Z Rheumatol (2016) 75:151–6. doi:10.1007/
s00393-015-0029-3 
44. Mammen AL. Statin-associated autoimmune myopathy. N Engl J Med (2016) 
374:664–9. doi:10.1056/NEJMra1515161 
45. Werner JL, Christopher-Stine L, Ghazarian SR, Pak KS, Kus JE, Daya NR, 
et  al. Antibody levels correlate with creatine kinase levels and strength in 
anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoim-
mune myopathy. Arthritis Rheum (2012) 64:4087–93. doi:10.1002/art.34673 
46. Iaccarino L, Pegoraro E, Bello L, Bettio S, Borella E, Nalotto L, et  al. 
Assessment of patients with idiopathic inflammatory myopathies and isolated 
creatin-kinase elevation. Auto Immun Highlights (2014) 5:87–94. doi:10.1007/
s13317-014-0063-1 
47. Liang C, Needham M. Necrotizing autoimmune myopathy. Curr Opin 
Rheumatol (2011) 23:612–9. doi:10.1097/BOR.0b013e32834b324b 
48. Miller T, Al-Lozi MT, Lopate G, Pestronk A. Myopathy with antibodies to 
the signal recognition particle: clinical and pathological features. J Neurol 
Neurosurg Psychiatry (2002) 73:420–8. doi:10.1136/jnnp.73.4.420 
49. Chung T, Christopher-Stine L, Paik JJ, Corse A, Mammen AL. The composi-
tion of cellular infiltrates in anti-HMG-CoA reductase-associated myopathy. 
Muscle Nerve (2015) 52:189–95. doi:10.1002/mus.24642 
50. Christopher-Stine L, Casciola-Rosen LA, Hong G, Chung T, Corse AM, 
Mammen AL. A novel autoantibody recognizing 200-kd and 100-kd proteins 
is associated with an immune-mediated necrotizing myopathy. Arthritis 
Rheum (2010) 62:2757–66. doi:10.1002/art.27572 
51. Hengstman GJ, ter Laak HJ, Vree Egberts WT, Lundberg IE, Moutsopoulos 
HM, Vencovsky J, et  al. Anti-signal recognition particle autoantibodies: 
marker of a necrotising myopathy. Ann Rheum Dis (2006) 65:1635–8. 
doi:10.1136/ard.2006.052191 
52. Romisch K, Miller FW, Dobberstein B, High S. Human autoantibodies against 
the 54 kDa protein of the signal recognition particle block function at multiple 
stages. Arthritis Res Ther (2006) 8:R39. doi:10.1186/ar1895 
53. Suzuki S, Hayashi YK, Kuwana M, Tsuburaya R, Suzuki N, Nishino I. 
Myopathy associated with antibodies to signal recognition particle: disease 
progression and neurological outcome. Arch Neurol (2012) 69:728–32. 
doi:10.1001/archneurol.2011.1728 
54. Allenbach Y, Drouot L, Rigolet A, Charuel JL, Jouen F, Romero NB, et  al. 
Anti-HMGCR autoantibodies in European patients with autoimmune necro-
tizing myopathies: inconstant exposure to statin. Medicine (Baltimore) (2014) 
93:150–7. doi:10.1097/MD.0000000000000028 
7Simon et al. Myositis in 2015
Frontiers in Immunology | www.frontiersin.org June 2016 | Volume 7 | Article 234
55. Reeves WH, Nigam SK, Blobel G. Human autoantibodies reactive with the 
signal-recognition particle. Proc Natl Acad Sci U S A (1986) 83:9507–11. 
doi:10.1073/pnas.83.24.9507 
56. Bronner IM, Hoogendijk JE, Wintzen AR, van der Meulen MF, Linssen 
WH, Wokke JH, et  al. Necrotising myopathy, an unusual presentation of 
a steroid-responsive myopathy. J Neurol (2003) 250:480–5. doi:10.1007/
s00415-003-1027-y 
57. Dalakas MC. Immunotherapy of myositis: issues, concerns and future pros-
pects. Nat Rev Rheumatol (2010) 6:129–37. doi:10.1038/nrrheum.2010.2 
58. Kassardjian CD, Lennon VA, Alfugham NB, Mahler M, Milone M. Clinical 
features and treatment outcomes of necrotizing autoimmune myopathy. 
JAMA Neurol (2015) 72:996–1003. doi:10.1001/jamaneurol.2015.1207 
59. Valiyil R, Casciola-Rosen L, Hong G, Mammen A, Christopher-Stine L. 
Rituximab therapy for myopathy associated with anti-signal recognition par-
ticle antibodies: a case series. Arthritis Care Res (Hoboken) (2010) 62:1328–34. 
doi:10.1002/acr.20219 
60. Curtin D, Costigan D, McCarthy C, Jansen M, Farrell M, Reid V, et al. Novel 
antibody associations in immune-mediated necrotising myopathy without 
inflammation. Ir J Med Sci (2014). doi:10.1007/s11845-014-1207-z 
61. Allenbach Y, Keraen J, Bouvier AM, Jooste V, Champtiaux N, Hervier B, et al. 
High risk of cancer in autoimmune necrotizing myopathies: usefulness of 
myositis specific antibody. Brain (2016). doi:10.1093/brain/aww054 
62. Grable-Esposito P, Katzberg HD, Greenberg SA, Srinivasan J, Katz J, Amato 
AA. Immune-mediated necrotizing myopathy associated with statins. Muscle 
Nerve (2010) 41:185–90. doi:10.1002/mus.21486 
63. Badrising UA, Maat-Schieman M, van Duinen SG, Breedveld F, van Doorn 
P, van Engelen B, et  al. Epidemiology of inclusion body myositis in the 
Netherlands: a nationwide study. Neurology (2000) 55:1385–7. doi:10.1212/
WNL.55.9.1385 
64. Rose MR, Group EIW. 188th ENMC international workshop: inclusion body 
myositis, 2-4 December 2011, Naarden, The Netherlands. Neuromuscul Disord 
(2013) 23:1044–55. doi:10.1016/j.nmd.2013.08.007 
65. Mendell JR, Sahenk Z, Gales T, Paul L. Amyloid filaments in inclusion body 
myositis. Novel findings provide insight into nature of filaments. Arch Neurol 
(1991) 48:1229–34. doi:10.1001/archneur.1991.00530240033013 
66. Askanas V, Engel WK, Alvarez RB. Light and electron microscopic localization 
of beta-amyloid protein in muscle biopsies of patients with inclusion-body 
myositis. Am J Pathol (1992) 141:31–6. 
67. Askanas V, Engel WK, Alvarez RB, Glenner GG. beta-Amyloid protein immu-
noreactivity in muscle of patients with inclusion-body myositis. Lancet (1992) 
339:560–1. doi:10.1016/0140-6736(92)90388-J 
68. Askanas V, Engel WK. Sporadic inclusion-body myositis: conformational 
multifactorial ageing-related degenerative muscle disease associated with 
proteasomal and lysosomal inhibition, endoplasmic reticulum stress, and 
accumulation of amyloid-beta42 oligomers and phosphorylated tau. Presse 
Med (2011) 40:e219–35. doi:10.1016/j.lpm.2010.11.024 
69. Fratta P, Engel WK, McFerrin J, Davies KJ, Lin SW, Askanas V. Proteasome 
inhibition and aggresome formation in sporadic inclusion-body myositis 
and in amyloid-beta precursor protein-overexpressing cultured human 
muscle fibers. Am J Pathol (2005) 167:517–26. doi:10.1016/S0002-9440(10) 
62994-X 
70. Nogalska A, D’Agostino C, Terracciano C, Engel WK, Askanas V. Impaired 
autophagy in sporadic inclusion-body myositis and in endoplasmic retic-
ulum stress-provoked cultured human muscle fibers. Am J Pathol (2010) 
177:1377–87. doi:10.2353/ajpath.2010.100050 
71. Dubourg O, Wanschitz J, Maisonobe T, Behin A, Allenbach Y, Herson S, et al. 
Diagnostic value of markers of muscle degeneration in sporadic inclusion 
body myositis. Acta Myol (2011) 30:103–8. 
72. Brady S, Squier W, Sewry C, Hanna M, Hilton-Jones D, Holton JL. A ret-
rospective cohort study identifying the principal pathological features useful 
in the diagnosis of inclusion body myositis. BMJ Open (2014) 4:e004552. 
doi:10.1136/bmjopen-2013-004552 
73. Arahata K, Engel AG. Monoclonal antibody analysis of mononuclear cells 
in myopathies. I: quantitation of subsets according to diagnosis and sites of 
accumulation and demonstration and counts of muscle fibers invaded by 
T cells. Ann Neurol (1984) 16:193–208. doi:10.1002/ana.410160206 
74. van der Pas J, Hengstman GJ, ter Laak HJ, Borm GF, van Engelen BG. Diagnostic 
value of MHC class I staining in idiopathic inflammatory myopathies. J Neurol 
Neurosurg Psychiatry (2004) 75:136–9. 
75. Benveniste O, Stenzel W, Hilton-Jones D, Sandri M, Boyer O, van Engelen 
BG. Amyloid deposits and inflammatory infiltrates in sporadic inclusion body 
myositis: the inflammatory egg comes before the degenerative chicken. Acta 
Neuropathol (2015) 129:611–24. doi:10.1007/s00401-015-1384-5 
76. Dalakas MC, Koffman B, Fujii M, Spector S, Sivakumar K, Cupler E. A con-
trolled study of intravenous immunoglobulin combined with prednisone in 
the treatment of IBM. Neurology (2001) 56:323–7. doi:10.1212/WNL.56.3.323 
77. Badrising UA, Maat-Schieman ML, Ferrari MD, Zwinderman AH, Wessels JA, 
Breedveld FC, et al. Comparison of weakness progression in inclusion body 
myositis during treatment with methotrexate or placebo. Ann Neurol (2002) 
51:369–72. doi:10.1002/ana.10121 
78. Rutkove SB, Parker RA, Nardin RA, Connolly CE, Felice KJ, Raynor EM. 
A pilot randomized trial of oxandrolone in inclusion body myositis. Neurology 
(2002) 58:1081–7. doi:10.1212/WNL.58.7.1081 
79. Muscle Study G. Randomized pilot trial of high-dose betaINF-1a in patients 
with inclusion body myositis. Neurology (2004) 63:718–20. doi:10.1212/01.
WNL.0000134675.98525.79 
80. Lindberg C, Trysberg E, Tarkowski A, Oldfors A. Anti-T-lymphocyte globulin 
treatment in inclusion body myositis: a randomized pilot study. Neurology 
(2003) 61:260–2. doi:10.1212/01.WNL.0000071852.27182.C7 
81. Dalakas MC, Rakocevic G, Schmidt J, Salajegheh M, McElroy B, Harris-
Love MO, et al. Effect of alemtuzumab (CAMPATH 1-H) in patients with 
inclusion-body myositis. Brain (2009) 132:1536–44. doi:10.1093/brain/
awp104 
82. Haubenberger D, Bittner RE, Rauch-Shorny S, Zimprich F, Mannhalter C, 
Wagner L, et  al. Inclusion body myopathy and Paget disease is linked to a 
novel mutation in the VCP gene. Neurology (2005) 65:1304–5. doi:10.1212/01.
wnl.0000180407.15369.92 
83. Guyant-Marechal L, Laquerriere A, Duyckaerts C, Dumanchin C, Bou J, 
Dugny F, et  al. Valosin-containing protein gene mutations: clinical and 
neuropathologic features. Neurology (2006) 67:644–51. doi:10.1212/01.
wnl.0000225184.14578.d3 
84. Eisenberg I, Avidan N, Potikha T, Hochner H, Chen M, Olender T, et al. The 
UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase gene 
is mutated in recessive hereditary inclusion body myopathy. Nat Genet (2001) 
29:83–7. doi:10.1038/ng718 
85. Badrising UA, Schreuder GM, Giphart MJ, Geleijns K, Verschuuren JJ, 
Wintzen AR, et al. Associations with autoimmune disorders and HLA class 
I and II antigens in inclusion body myositis. Neurology (2004) 63:2396–8. 
doi:10.1212/01.WNL.0000148588.15052.4C 
86. Larman HB, Salajegheh M, Nazareno R, Lam T, Sauld J, Steen H, et  al. 
Cytosolic 5’-nucleotidase 1A autoimmunity in sporadic inclusion body 
myositis. Ann Neurol (2013) 73:408–18. doi:10.1002/ana.23840 
87. Pluk H, van Hoeve BJ, van Dooren SH, Stammen-Vogelzangs J, van der 
Heijden A, Schelhaas HJ, et  al. Autoantibodies to cytosolic 5’-nucleotidase 
1A in inclusion body myositis. Ann Neurol (2013) 73:397–407. doi:10.1002/
ana.23822 
88. Rojana-udomsart A, James I, Castley A, Needham M, Scott A, Day T, 
et  al. High-resolution HLA-DRB1 genotyping in an Australian inclusion 
body myositis (s-IBM) cohort: an analysis of disease-associated alleles and 
diplotypes. J Neuroimmunol (2012) 250:77–82. doi:10.1016/j.jneuroim.2012. 
05.003 
89. Schmidt J, Barthel K, Zschuntzsch J, Muth IE, Swindle EJ, Hombach A, et al. 
Nitric oxide stress in sporadic inclusion body myositis muscle fibres: inhi-
bition of inducible nitric oxide synthase prevents interleukin-1beta-induced 
accumulation of beta-amyloid and cell death. Brain (2012) 135:1102–14. 
doi:10.1093/brain/aws046 
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be 
construed as a potential conflict of interest.
Copyright © 2016 Simon, Marie, Jouen, Boyer and Martinet. This is an open-access 
article distributed under the terms of the Creative Commons Attribution License (CC 
BY). The use, distribution or reproduction in other forums is permitted, provided the 
original author(s) or licensor are credited and that the original publication in this 
journal is cited, in accordance with accepted academic practice. No use, distribution 
or reproduction is permitted which does not comply with these terms.
